What is a gene vaccine

Vaccine development

 

BNT162

Sponsor: BioNTech RNA Pharmaceuticals

Vaccine category: SARS-CoV-2 virus mRNA

Description of the vaccine: mRNA encased in lipid nanoparticles, which codes for the spike protein of SARS-CoV-2

Test type: phase I / II + phase I / II + phase III

Planned number of subjects: 200, 7,600 and 30,000 (-> 44,000)

Results: https://investors.biontech.de/press-releases

Interim results on effectiveness and safety

 

mRNA-1273

Sponsor: National Institute of Allergy and Infectious Diseases (Moderna)

Vaccine category: SARS-CoV-2 virus mRNA

Description of the vaccine: mRNA encased in lipid nanoparticles, which codes for the spike protein of SARS-CoV-2.

Trial type: phase I + phase II + phase III

Planned number of subjects: 105 + 600 + 30,000

Results: https://www.modernatx.com/cove-study

Interim results on effectiveness and safety

 

INO-4800

Sponsor: Inovio Pharmaceuticals

Vaccine category: SARS-CoV-2 virus DNA

Vaccine Description: Electroporated DNA plasmid that encodes the spike protein.

Test type: phase I + phase II / III

Planned number of subjects: 40 and 6,578 (phase II / III)

Results: https://www.inovio.com/our-focus-serving-patients/covid-19/

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial (EClinical Medicine, December 23, 2020)

 

GX-19

Sponsor: Genexine Inc.

Vaccine category: SARS-CoV-2 virus DNA

Vaccine Description: Electroporated DNA plasmid that encodes the spike protein.

Test type: phase I / IIa

Planned number of subjects: 40 (phase I) and 150 (phase IIa)

Results: http://www.genexine.com/

 

AG0301-COVID19

Sponsor: AnGes Inc., Japan Agency for Medical Research and Development

Vaccine category: SARS-CoV-2 virus DNA

Vaccine description: DNA plasmid coding for the spike protein

Test type: Phase I / II

Intended number of subjects: 30

Results: https://www.anges.co.jp/en/

 

nCov Vaccine

Sponsor: Cadila Healthcare Ltd

Vaccine category: SARS-CoV-2 virus DNA

Vaccine description: DNA plasmid coding for the spike protein

Trial type: Phase I / II

Estimated number of subjects: 1048

Results: https://zyduscadila.com/

 

COVAC1 (LNP-nCoVsaRNA)

Sponsor: Imperial College London

Vaccine category: SARS-CoV-2 virus mRNA

Description of the vaccine: mRNA encased in lipid nanoparticles, which codes for the spike protein of SARS-CoV-2

Trial type: phase I + phase II

Intended number of subjects: 300

Results:http://www.imperial.ac.uk/news

 

CVnCoV Vaccine

Sponsor: Curevac

Vaccine category: SARS-CoV-2 virus mRNA

Description of the vaccine: mRNA encased in lipid nanoparticles, which codes for the spike protein of SARS-CoV-2

Trial type: phase I + phase II

Anticipated number of subjects: 168 and 691

Results:https://www.curevac.com/covid-19

CureVac's COVID-19 vaccine triggers immune response in Phase I trial (2.11.2020)

 

SARS-CoV-2 mRNA vaccine

Sponsor: Yunnan Walvax Biotechnology Co.

Vaccine category: SARS-CoV-2 virus mRNA

Vaccine description: mRNA coding for the SARS-CoV-2 spike protein

Trial type: Phase I

Estimated number of subjects: 168

Results:http://www.walvax.com/Model/25.aspx

 

ARCT-021

Sponsor:Arcturus Therapeutics, Inc.

Vaccine category: SARS-CoV-2 virus mRNA

Description of the vaccine: mRNA encased in lipid nanoparticles, which codes for the spike protein of SARS-CoV-2

Trial type: Phase I / II

Intended number of subjects: 85

Results: https://ir.arcturusrx.com/press-releases

 

ChulaCov19

Sponsor:Chulalongkorn University

Vaccine category: SARS-CoV-2 virus mRNA

Description of the vaccine: mRNA encased in lipid nanoparticles, which codes for an antigen of SARS-CoV-2

Trial type: Phase I

Estimated number of subjects: 96

Results: https: //www.chula.ac.th/en/news-and-knowledge/cu-news/

 

Covigenix VAX-001

Sponsor: Entos Pharmaceuticals Inc.

Vaccine category: SARS-CoV-2 virus DNA

Vaccine description: administered DNA plasmid that codes for the nucleocapsid protein.

Test type: Phase I

Intended number of subjects: 72

Results: https://www.entospharma.com/news

 

CORVax12

Sponsor: Providence Health & Services

Vaccine category: SARS-CoV-2 virus DNA

Vaccine description: DNA plasmid encoding the spike protein, with or without a DNA plasmid encoding the IL-12 protein

Trial type: Phase I

Intended number of subjects: 36

Results: https://www.providence.org/news/coronavirus-blog

 

GLS-5310

Sponsor: GeneOne Life Science, Inc.

Vaccine category: SARS-CoV-2 virus DNA

Vaccine description: DNA plasmid that codes for the spike protein and an antigen.

Trial type: Phase I / II

Estimated number of subjects: 345

Results: http://genels.com/en/sub/pipeline/pipe.asp